©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jun 26, 2017; 9(6): 89-97
Published online Jun 26, 2017. doi: 10.4252/wjsc.v9.i6.89
Published online Jun 26, 2017. doi: 10.4252/wjsc.v9.i6.89
Skeletal muscle generated from induced pluripotent stem cells - induction and application
Yuko Miyagoe-Suzuki, Shin’ichi Takeda, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan
Author contributions: Miyagoe-Suzuki Y primarily wrote the manuscript; Takeda S supervised the writing.
Supported by The Program for Intractable Diseases Research utilizing Disease-specific iPS cells (Japan Agency for Medical Research and Development: AMED), No. 15652069; Projects for Technological Development (K1), from the Research Center Network for Realization of Regenerative Medicine (AMED); Intramural Research Grants for Neurological and Psychiatric Disorders of NCNP, No. 27-7; Grant-in-Aid for Scientific Research (C) (Japan Society for the Promotion of Science), No. 16744921.
Conflict-of-interest statement: There is no conflict of interest.
Correspondence to: Yuko Miyagoe-Suzuki, MD, PhD, Section Chief, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan. miyagoe@ncnp.go.jp
Telephone: +81-42-3461720 Fax: +81-42-3461750
Received: January 29, 2017
Peer-review started: February 13, 2017
First decision: March 27, 2017
Revised: May 9, 2017
Accepted: May 18, 2017
Article in press: May 19, 2017
Published online: June 26, 2017
Processing time: 147 Days and 13 Hours
Peer-review started: February 13, 2017
First decision: March 27, 2017
Revised: May 9, 2017
Accepted: May 18, 2017
Article in press: May 19, 2017
Published online: June 26, 2017
Processing time: 147 Days and 13 Hours
Core Tip
Core tip: Skeletal muscle cells induced from patient induced pluripotent stem cells (iPSCs) are useful for the study of pathogenesis and drug development. The derivation of mature myofibers is required for disease modeling. On the other hand, human iPSCs from healthy donors are likely to be a cell source for cell therapy. For safe cell transplantation, non-oncogenic cells are needed.